Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 15,000,000
    Countries
    Sector(s)
    Germany : € 15,000,000
    Services : € 15,000,000
    Signature date(s)
    20/12/2023 : € 15,000,000
    Link to source

    Summary sheet

    Release date
    13 March 2024
    Status
    Reference
    Signed | 20/12/2023
    20220749
    Project name
    Promoter - financial intermediary
    NVISION IMAGING TECHNOLOGIES (IEU LS)
    NVISION IMAGING TECHNOLOGIES GMBH
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 15 million
    EUR 53 million
    Location
    Sector(s)
    • Services - Professional, scientific and technical activities
    Description
    Objectives

    The project concerns the promoter's development of a quantum-based platform to transform existing MRIs into metabolic imagers at scale, enabling the early assessment of oncology treatment efficacy.

    The promoter is developing superior diagnostics in the field of oncology by providing information of a tumours' metabolic activity. This allows fast adaptation of oncology therapies. As such, this project will improve treatment options for cancer patients, in turn contributing positively to quality of life as well as overall survival.

    Additionality and Impact

    The project concerns an operation under Invest EU. The project is eligible in line with Annex II of the Regulation as it relates to (5)(g) new and effective and accessible healthcare products. The purpose of the loan is to provide direct, equity-type financing under EIB's Venture Debt Instrument to support Research, Development and Innovation ("RDI") activities of the innovative company "NVision", a medical technology company based in Germany. The financing of this project addresses the failure in financial markets for RDI, arising from limited access to commensurate financing because of factors such as information asymmetries, misalignment of incentives, etc. NVision, thanks to its strong expertise in quantum physics, is developing a novel diagnostic method improving current MRI imaging, which would allow for rapid prediction of oncology treatment response. By creating knowledge externalities, the project is expected to provide significant socio-economic benefits, will strengthen Germany and Europe's position in the field of cancer therapies, and will help to create and retain skilled staff engaged in the Company's RDI activities. Thanks to the support of InvestEU, the EIB may provide a flexible long-term financing that limits significant cash outflows in the short to medium term, thereby enabling the company to focus on investing in innovation and growth. By contributing to extending the cash runway of a highly innovative but high-risk early-stage company with no access to commercial debt, the EIB financing is expected to de-risk the project, create a crowd-in signaling effect, and allow the company to accelerate its development. The EIB could not provide such type of financing support, or not to the same extent or at the same quantum, without support from the InvestEU guarantee.

    Environmental aspects
    Procurement

    The project concerns investments in research and development activities carried out by the promoter and its partners in existing facilities without changing their already authorised scope. The research and development activities of the project do not fall under neither Annex I or Annex II of the Environmental Impact Assessment (EIA) EU Directive 2014/52/EU amending 2011/92/EU.

    The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB's guidelines for private sector projects. The EIB will verify details during the project due diligence.

    Milestone
    Under appraisal
    Approved
    Signed
    19 October 2023
    20 December 2023
    Related projects
    Link to source

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - NVISION IMAGING TECHNOLOGIES (IEU LS)
    Publication Date
    21 Mar 2024
    Document language
    Main Topic
    Lending
    Document Number
    195987836
    Document Focus
    Environmental Information
    Project Number
    20220749
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications